Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology

Diagnostic Microbiology and Infectious Disease

Volumn 41, Issue 3, 2001, Pages 121-126

  Keele, Douglas J ^a   DeLallo, Veronica C ^a   Lewis, Russell E ^b   Ernst, Erika J ^a   Klepser, Michael E ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

Author keywords

Amphotericin B; Antifungals; Candida albicans; Candida neoformans; Combination; Flucytosine; Time kill

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EVALUATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG SYNERGISM; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 0035669255     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00297-8     Document Type: Article

References (27)

1. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
2. Pharmacology and pharmacokinetics of traditional systemic antifungal agents
3. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis
4. Clinical use of systemic antifungal agents
5. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
6. Clinical pharmacokinetics of systemic antifungal drugs
7. Antimicrobial Combinations
8. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time
9. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp.
10. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
11. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options
12. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
13. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis
14. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods
15. Strategies in the treatment of systemic fungal infections
16. Phenotypic resistance to amphotericin B in Candida albicans: Relationship to glucan metabolism
17. Amphotericin B use in a community hospital, with special emphasis on side effects
18. Method of reliable determination of minimal lethal antibiotic concentrations
19. Interactions in vitro between polyenes and imidazoles against yeasts
20. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
21. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia
22. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis
23. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
24. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
25. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
26. Risk factors for hospital-acquired candidemia. A matched case-control study